Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03993353 · ClinicalTrials.gov registry record · Phase 2
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
A Phase 2 study of Cancer and Head and Neck Cancer, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT03993353 is a Phase 2 study of Cancer and Head and Neck Cancer that has completed, run by University of California, San Diego. The registered enrollment target is 7 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03993353, a Phase 2 study of Cancer and Head and Neck Cancer, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Tadalafil
Study Locations (1)
California
- UCSD Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03993353
The ClinicalTrials.gov registry entry for NCT03993353 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03993353 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03993353 about?
NCT03993353 is a clinical study titled "Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer". This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
What is the current status of trial NCT03993353?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2020-04-07. Estimated completion is 2024-01-09.
What conditions does trial NCT03993353 study?
This clinical trial studies the following conditions: Cancer, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Cancer Metastatic.
What interventions are being tested in trial NCT03993353?
The interventions under investigation include: Pembrolizumab (DRUG), Tadalafil (DRUG).
Who is sponsoring clinical trial NCT03993353?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03993353 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.